Gujarat Themis Biosyn Ltd
NSE: GUJTHEM · Pharmaceuticals · sector
₹337.90NSE close 2026-10-26
Key numbers
Market cap₹3,682 cr
Price₹337.90
52w high / low₹479 / ₹225
P/E75.6xSector median 27.9x
P/B12.8xSector median 2.9x
Book value₹26.4
Dividend yield0.20%Sector median 0.48%
ROE18.2%Sector median 11.7%
ROCE15.6%Sector median 12.3%
OPM47.4%Sector median 14.0%
Debt / equity0.56xSector median 0.16x
EV/EBITDA46.5xSector median 18.6x
Interest cover14.9x
Current ratio1.12x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹6 cr vs borrowings ₹160 cr (FY26): borrowings are higher by ₹154 cr.
- Operating profit covered interest 14.9x in the last 12 months.
- No promoter shares are pledged.
- Promoter holding fell by 11.53 percentage points in a year, to 59.33% (2026-09-30).
- Other income was 5% of net profit in the last 12 months.
- Dividend paid in 1 of the last 2 financial years.
- Price ₹337.90 on 2026-10-26: -29.5% from the 52-week high, +50.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹469.90 · low ₹238.59
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 38 | 36 | 42 | 43 | 44 | 44 |
| EBITDA | 16 | 14 | 21 | 21 | 19 | 21 |
| OPM % | 42.5% | 38.8% | 49.5% | 49.1% | 43.8% | 47.5% |
| Other income | 1 | 0 | 1 | 0 | 1 | 0 |
| Net profit | 12 | 9 | 14 | 12 | 11 | 11 |
| EPS (₹) | 1.10 | 0.83 | 1.31 | 1.14 | 1.00 | 1.02 |
| Revenue YoY | +17.2% | +22.1% | ||||
| Profit YoY | -9.2% | +22.2% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY25 | FY26 | TTM |
|---|---|---|---|
| Revenue | 151 | 166 | 174 |
| EBITDA | 69 | 76 | 82 |
| Net profit | 49 | 47 | 49 |
| EPS (₹) | 4.48 | 4.28 | 4.47 |
| Revenue growth | +10.0% | – | |
| Profit growth | -4.3% | – | |
| Dividend / share (₹) | – | 0.67 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | -23.4% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 248 | 288 |
| Borrowings | 30 | 160 |
| Cash & equivalents | 13 | 6 |
| Total assets | 301 | 503 |
| Fixed assets | 41 | 287 |
| Capital work in progress | 184 | 121 |
| Investments | 0 | 3 |
| Receivables | 31 | 61 |
| Inventory | 5 | 15 |
| Payables | 15 | 37 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 91 | 49 |
| Cash from investing | -112 | -172 |
| Cash from financing | 26 | 115 |
| Capex | 116 | 173 |
| Free cash flow | -25 | -124 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 19.6% | 16.2% |
| ROCE % | 23.7% | 14.5% |
| Debtor days | 76 | 134 |
| Inventory days | 75 | 263 |
| Payable days | 218 | 625 |
| Cash conversion cycle (days) | -67 | -228 |
| Working capital days | 76 | 21 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 59.33% |
| FIIs | 3.80% |
| DIIs | 12.65% |
| of which Mutual funds | 9.63% |
| of which Insurance | 2.17% |
| Government | 0.00% |
| Public (non-institutions) | 24.22% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 70.86% | 70.86% | 70.86% | 70.86% | 70.86% | 70.86% | 59.33% | 59.33% |
| Promoter group | % |
|---|---|
| Pharmaceutical Business Group [india] Ltd | 38.97% |
| Themis Medicare Limited | 17.50% |
| Sachin Dinesh Patel | 2.32% |
| Dinesh Shantilal Patel, Jayshree Dinesh Patel, Sachin Dinesh Patel (Trustees of Vividhmargi Trust) | 0.51% |
| Anay Rupen Choksi | 0.02% |
| Nysha Rupen Choksi | 0.02% |
| Jayshree D Patel | 0.00% |
| Dinesh Shantilal Patel | 0.00% |
| Reena S Patel | 0.00% |
| Public holders above 1% | % |
|---|---|
| Quant Mutual Fund - Quant Manufacturing Fund | 7.47% |
| Ayushmat Ltd | 2.55% |
| Kotak Mahindra Life Insurance Company Ltd | 2.17% |
| Bank of India Flexi CAP Fund | 1.63% |
28,781 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| GUJTHEM | ₹3,682 cr | 75.6x | 12.8x | 18.2% | 15.6% | 47.4% | – | 0.20% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-23 | Dividend | Dividend - Re 0.67 Per Share |
| 2025-09-04 | Dividend | Dividend - Re 0.67 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacture of Pharmaceuticals & Medicinal Chemicals: Engaged in the manufacturing of fermentation- based pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs)
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | GUJTHEM |
| BSE code | 506879 |
| ISIN | INE942C01045 |
| Face value | ₹1.0 |
| Incorporated | 1981-12-11 |
| Website | www.gtbl.in |
| Plants (India / abroad) | 1 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.